Skip to main content
Cookies Policy
Detailed information on the use of cookies on this website is provided in our Privacy Policy. By closing this message and proceeding, you consent to our use of cookies in accordance with our Cookies Policy.

Half-Billion Biomedical Innovation Fund kicks off

Friday, 16 Dec 2016


Government ends year on a NISA high.

The government’s national innovation and science agenda (NISA) was largely dormant in 2016, but is finishing with a flurry as two of the biggest ticket items are brought online in the space of a week.

Having managed to sneak the $200 million CSIRO Innovation Fund just inside NISA’s first year, the government has also now jumpstarted its $500 million Biomedical Translation Fund.

The public purse contribution to each fund is $70 million and $250 million respectively, with the remainder drawn from royalties and private sector investment.

Three venture capital fund managers have been appointed to oversee the biomedical fund, which is designed to get innovation out of the lab and to the patient.

Brandon Capital Partners has been licensed to manage $115 million in Commonwealth capital and $115 million in private capital, the Minister for Industry, Innovation and Science Greg Hunt said.

The private sector funds it looks after have been drawn from biopharmaceutical investor CSL Limited and from several superannuation funds.

“Currently, promising Australian medical discoveries are often sold to large offshore pharmaceutical companies at early stages of development due to lack of investment capital available to the sector in Australia,” Brandon Capital Partner said.

It will focus its investments on companies with medical research projects at advanced pre-clinical, Phase I and Phase II stages of development, enabling them to pursue later-stage product development onshore.

Brandon called the biomedical translation fund a “once-in-a-generation initiative to make Australia a global leader in the commercialisation of biomedical discoveries.”

Also within the biomedical fund will be OneVentures, which will have a total pot of $170 million, and BioScience Managers with a pot “of at least $100 million.”

Sydney-based OneVentures already has $170 million in funds under management, and has invested in a range of tech start-ups including e-learning company Smart Sparrow and biotech firm Clinical Genomics.

Click HERE to read the full article.